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Systems biology approaches to a rational drug discovery paradigm 
Philip Prathipati* and Kenji Mizuguchi 
National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saito-Asagi, 
Ibaraki City, Osaka- 567-0085 
Abstract: Ligand- and structure-based drug design approaches complement phenotypic 
and target screens, respectively, and are the two major frameworks for guiding early-stage 
drug discovery efforts. Since the beginning of this century, the advent of the genomic era 
has presented researchers with a myriad of high throughput biological data (parts lists and 
their interaction networks) to address efficacy and toxicity, augmenting the traditional 
ligand- and structure-based approaches. This data rich era has also presented us with 
challenges related to integrating and analyzing these multi-platform and multi-dimensional 
datasets and translating them into viable hypotheses.  
Hence in the present paper, we review these existing approaches to drug discovery research and 
argue the case for a new systems biology based approach. We present the basic principles and 
the foundational arguments/underlying assumptions of the systems biology based approaches to 
drug design. Also discussed are systems biology data types (key entities, their attributes and their 
relationships with each other, and data models/representations), software and tools used for both 
retrospective- and prospective-analysis, and the hypotheses that can be inferred. In addition, we 
summarize some of the existing resources for a systems biology based drug discovery paradigm 
(open TG-GATEs, DrugMatrix, CMap and LINCs) in terms of their strengths and limitations. 
Keywords: systems biology, drug discovery, chemoinformatics, chemoproteomics, 
chemogenomics, genomics, phenomics 
INTRODUCTION 
Computer-assisted drug design† approaches have traditionally been classified into ligand- and 
structure-based approaches.[1] [Since this review covers a wide range of research areas, we have 
prepared a glossary for key technical terms (indicated with a dagger symbol) in Supplementary 
File 1.] The former approach, based on the idea of similar chemical structures having similar 
pharmacological effects, led to successful therapeutics even when the mode of action (MOA)† 
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was unknown[2]b,2 The ligand-based approach† mimics medicinal chemistry strategies, such as 
optimizing physicochemical properties, and is widely used and regarded as the most successful 
technique to date3. However, this approach does not offer a rational design† strategy. 
Furthermore, most often the structure-activity relationships† (SAR) guided multi-objective 
optimization† (against both the phenotype† and toxicity†) is fraught with difficulties.1 This 
problem has been attributed to key polar functional groups† or substructures [such as basic 
fragments for G-protein coupled receptors and acid/serine proteases4 (figure 1), or acidic 
fragments for phosphatases], which have to retain a particular physicochemical property† (e.g., 
“basic” in figure 1) for the on-target activity but such a property may be incompatible with 
favorable absorption, distribution, metabolism, excretion and toxicity (ADMET†) profiles. 1 
The latter, structure-based approach† also presents its own set of problems; methods for 
docking a compound into a single well-defined protein structure are reasonably mature but it 
is still a challenge to deal with multiple (functionally distinct) conformational states of the 
target protein. Furthermore, small molecules can interact with numerous other proteins (“off-
targets”) and there is also no rational procedure for understanding how the target-interaction 
profiles (“chemoproteomic profiles”; see section 3.5 for more details) correlate with the 
phenotype (Fig. 2).5, 6 
However, since the beginning of this century, the advent of the genomic era has presented 
researchers with a myriad of high throughput (HT) biological data† (parts lists and their 
interaction networks), which can assist in the optimization of efficacy and ADMET profiles in 
the traditional ligand- and structure- based approaches. This data rich era has, on the other hand, 
presented us with challenges related to integrating and analyzing multi-platform and multi-
dimensional datasets and translating them into viable hypotheses.  
Hence in the following sections, we elaborate on the existing approaches to drug discovery 
research and argue the case for a new systems biology based approach (section 1). We present 
the basic principles and the foundational arguments/underlying assumptions of the systems 
biology based approaches to drug design (section 2). We then discuss systems biology data types 
(key entities, their attributes and their relationships with each other), hypotheses that can be 
inferred, and software and tools used for both retrospective- and prospective-inferences (section 
3). We also review data models/representations that capture systems biology data types (section 
4), In addition, we summarize some of the existing resources for a systems biology based drug 
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discovery paradigm (open TG-GATEs, DrugMatrix, CMap and LINCs) in terms of their 
strengths and limitations (section 5). Finally, we review recent machine learning approaches for 
analyzing systems biology data (section 6). 
 
 
Figure 1: The advantages of structure-based approaches augmenting ligand-based approaches 
are exemplified using FXa inhibitors Dabigatran (A and C) and Rivaroxaban (B and D). Using 
a ligand-based approach, a basic fragment at P1 site (circled in A and C) was shown to be 
essential for FXa inhibition. Hence, the optimization strategy involved exploring other basic 
fragments at this site, which led to unfavorable ADMET profiles. A structure-based approach 
was used for replacing the basic amidine fragment of Dabigatran at the P1 pocket with a neutral 
chlorothiophene fragment by exploiting FXa’s binding site information and the full range of 
intermolecular interactions such pi-pi, cation-pi and anion-pi, in addition to the usual hydrogen 
bonding, hydrophobic and salt bridge interactions. This strategy has led to the design of the 
new inhibitor Rivaroxaban (B and D) with favorable ADMET profiles. For more details, the 




Figure 2: The cancer model built using the fruit fly Drosophila pathway† data was used to 
rationally arrive at a compound (AD80) that was shown to inhibit four of the 10 selected cancer 
targets, dRET, Src, Raf and S6K. This chemoproteomic profile (inhibiting these four targets 
out of the 10) was associated with high efficacy and low toxicity in whole animal screening.. 
Further SAR analysis also led to the identification of dTOR as an anti-target responsible for 
toxicity. AD80 proved far more effective and less toxic than standard cancer drugs, which 
generally focus on a single target. This study by Dar et al.6 was the first time that whole-animal 
screening has been used in a rational, step-wise approach to identifying favorable 
chemoproteomic profiles and laid the case for a rational systems biology approach to drug 
discovery. For a more general discussion of chemoproteomics, see section 3.5. 
1. THE CASE FOR A SYSTEMS BIOLOGY OR NETWORK BASED DRUG 
DISCOVERY PARADIGM  
1.1 From phenotypic and target based screening to systems biology based 
screening 
In the pre-genomic era, two broad types of screens have sequentially dominated early-stage 
drug development—phenotypic screens and target† 
-based screens.7 The former quantifies the effects (phenotypes) that compounds induce in cells8 
and tissues. The correlation between the phenotypes and the compounds’ chemical structures 
is studied and incorporated into ligand-based in silico drug design efforts. The latter, target-
based screening assesses the effect of compounds on a purified target protein via in vitro† assays 
and is supported by structure-based computer-aided drug design techniques. These 
computational methods have fundamental limitations as described in the previous section, as 
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well as technical limitations discussed in ref1. To address the technical limitations, integrated 
HT computational protocols have been also proposed, combining ligand- and structure-based 
approaches.1,9 Structure-based approaches were integrated into ligand-based approaches with 
a view to select the model that reflects biological reality,9a, 10 while ligand-based models were 
integrated into structure-based models to address issues related to pose prediction and scoring 
functions.1,9c, 9d, 11 
One important technical limitation in these computational methods is the accuracy with which 
molecular recognition events are captured. Thus, molecular dynamics† (MD)12 simulations and 
quantum chemical calculations†13 such as Density Functional Theory (DFT) using graphics 
processing units (GPUs) can complement the traditional HT in silico techniques. in drug 
discovery research. The GPUs have greatly mitigated the computer scalability issues by 
accelerating the calculations tens of times. While MDs simulations can identify cryptic or 
allosteric binding sites,14 enhance traditional virtual-screening methodologies,15 and aid in the 
direct prediction of ligand binding energies, quantum chemistry calculations based on ab initio 
and DFT16 provide estimations of several physicochemical properties with increasing accuracy 
and establish data-driven sound relationships between structure and observable properties. 
With constant improvements in both computer power and algorithm design, MD simulations 
and quantum chemical calculations are likely to play an increasingly important role in the 
development of novel pharmacological therapeutics. 
However, even these integrated and accurate in silico approaches have proved insufficient for 
compound prioritization, because of difficulties in correlating phenotypic and target-based 
screens.17 For example, before the advances in molecular biology, phenotypic screens were 
primarily used with the hope of subsequently identifying the target or targets of intervention.18 
However, target identification and validation† proved difficult or impossible in most instances.7 
Hence in the last few decades, phenotypic† screens were mostly replaced with target screens, 
in which the target was validated with genetic studies, in early stages of drug discovery 
research.19 However, the over-reliance on target screening manifested as reduced discovery of 
first in class drugs.20 
Thus, integrative systems biology based screening methods were proposed as a solution, which 
combine elements of both phenotypic and target-based screens. This integrated framework 
hopes to expand and augment target-based screening by providing chemical validation of drug 
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targets, i.e., identifying the target or targets that are modulated by the candidate molecule when 
the desired phenotype is observed.21 
1.2 Use of gene†/protein/metabolite profiles as surrogates for phenotypes 
For a realistic application of a HT systems biology based integrative approach, phenotypic 
screens represent a bottleneck and present two major problems. First, phenotypes are difficult 
to quantify22 and second, running phenotypic screens (quantification of observable traits) for 
complex multifactorial diseases such as cancer, diabetes and cardiovascular diseases have 
logistic difficulties.23 For instance, according to the current cancer drug discovery paradigm, a 
rare population of tumor cells with stem cell characteristics (known as cancer stem cells) are 
considered to be responsible for tumor growth and metastasis and are the focus of much 
attention. However, monitoring and quantifying cancer stem cell content presents considerable 
challenges, including a) the requirements of serial biopsies of the tumor or b) counting the 
number of cells with a particular stem cell marker such as a surface protein or c) injecting the 
treated cancer stem cells into immune-deficient mice to see if they form tumors. Hence gene 
expression† signatures that correlate with “stemness” and are sensitive to chemotherapy are 
often used. 23 In a similar vein, the use of the gene/protein/metabolite expression/concentration 
signatures as surrogates for many other phenotypic endpoints has steadily been gaining 
acceptance in drug discovery and toxicological research.24 Huntington’s disease and 
Congenital adrenal hyperplasia are two examples where elevated metabolite profiles such as 
hydroxykynurenine and quinolinate levels and decreased metabolite profiles such as 
aldosterone and cortisol are used to the respective phenotypic states. Metabolomics is a study 
that aims to characterize the metabolome† (all endogenous metabolites found in cells and body 
fluid) under different conditions (for example, in disease states]. 25,26,27,28 Metabolomics can 
not only help us illustrate the underlying molecular disease-causing mechanisms but also gain 
broad recognition in discovery of metabolic signatures† [biomarkers] for disease diagnosis. 
25,26,27,28 
1.3 Integrative systems biology or network based drug discovery paradigm 
Given this background, systems biology approaches analyze how genes†, proteins, metabolites† 
and other molecular profiles and their interactions are maintained in health and how they 
become perturbed by genetic and environmental stressors and cause disease (“cause-effect 
mechanisms”).29 Thus the in silico systems biology or network-based drug discovery paradigm 
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attempts to model all major components and processes involved in early stages of drug 
discovery and development as described in figure 3.30 More specifically, the elucidation of 
cause-effects mechanisms can be realized in three ways: (a) a HT bioinformatics† approach for 
analyzing retrospectively the cause-effect mechanisms (such as master regulators of 
phenotypes or cellular states or enriched substructures associated with toxicity or 
pharmacological activity), (b) advanced machine learning methods for prospective predictions, 
or (c) both (a) and (b) together in one integrated protocol. We will describe these protocols in 
more detail in sections 3 and 6. 
The analysis of cause-effect mechanisms in chemoinformatics or chemoproteomics (see Table 
1 in section 3) may be relatively straightforward for the following reason. These studies deal 
with a matrix of whether a particular compound interacts with a particular protein 
(chemoproteomics) or whether a particular chemical possesses a particular substructure 
(chemocinformatics). Elucidating the cause-effect relationships in chemoproteomics involves 
identifying statistically significant associations between common structural features (cause) 
and protein-interaction profiles (effects). This analysis is straightforward, because we model 
direct binding events in isolated protein (in vitro) assays.  
However, a proper analysis of cause effect mechanisms in chemogenomics, genomics and 
phenomics† (see section 3 for the definitions) additionally requires the use of 
qualitative/quantitative pathway models for understanding the paths between the perturbed 
elements and the manifested outcomes.31 For instance, chemogenomics is the study of changes 
in gene expression profiles induced by chemical compounds. Thus the chemically induced gene 
expression signature can only be interpreted by modeling protein and gene networks†. 
[Chemicals binding to proteins transmit the signal to transcription† factors (TFs), which 
modulate gene expression.]32 Genomics and phonemics studies typically analyze the changes 
in gene expression profiles in diseased states induced from normal states by non-chemical 
perturbations. They include: (a) natural substrates (e.g., hormones, neurotransmitters, extra-
cellular signals/factors), (b) RNAi† (SiRNA, shRNA) (c) genome† editing (CRISPR) for 
knockdown or knockout, and (d) cDNA constructs for overexpression of master regulators†. 
These studies also require the use of gene regulatory networks together with protein and 




Systems biology using qualitative/quantitative models as part of the cause effect 
elucidation efforts attempts to understand the following elements. First, it concerns the 
structure of the biological system, i.e., all the elements linking the signal trigger (e.g., ligand 
binding to its cell-surface receptor) through the diverse pathways and mediators to a specific 
set of regulator proteins (such as TFs) that are responsible for altering the expression of a large 
number of genes, which then gives rise to phenotypic changes. (Such a structure is known as 
the bow-tie architecture34 because the signal converges to a small number of regulator proteins 
at the knot region and then diverges.)  The second element is the dynamics of the system by 
constructing predictive qualitative or quantitative models. Third, we need to identify “control 
elements” based on the predictive model simulations. These control proteins regulate the 
information flux between the input and the output and are also called bottleneck elements. 
These bottleneck elements are often prioritized as drug targets. Forth, we also need to 
understand how the system is constructed by combining known network motifs (i.e., repeating 
subnetworks such as feed-forward and other regulatory loops).  
Thus, to implement a systems biology approach to drug discovery research, we need to 
integrate chemoinformatic, proteomic, genomic, phenomic, chemoproteomic, chemogenomic 
data together with qualitative and quantitative cell signaling models.34 This approach, in 
addition to elucidating the cause-effect mechanism, can also identify a collection of modifiable 
drug targets and predict the effect of single- or combinatorial-drug treatments. The modulation 
of multiple targets may be required, because in most instances, phenotypes have back-up or 
alternate survival mechanisms, which also need to be perturbed to achieve phenotypic 
transition.  
Although many compound and target prioritization methods have been proposed, most 
of them are not based on the systems biology framework as described above. For example, 
compounds and targets that match a given set of proteomic, genomic or metabolomic profiles 
can be prioritized by searching appropriate databases such as ChEMBL,35 BindingDB36, 
TargetMine37, and Possum38 for proteomics,, cMap,39 CIDD,40 Toxygates41, GSEA42, and 
QSTAR project43 for genomics, and MSEA44 and MetaboAnalyst45 for metabolomics. The 
application of integrated approaches such as Galahad46, Expression2Kinases47, and 
CellNOptR48 which uses both genomic (or proteomic) profiles and protein-protein interaction 
(PPI) data, is also gaining attention. In its essence, all these prioritization processes involve 
comparing a molecular profiles (e.g., protein-target interaction or gene expression response) 
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associated with a chemical with a database of disease or pathway signatures such as MSigDB49, 
GeneSigDB50, and EnrichR51. The comparisons can be performed using a variety of association 
measures39, 52, but have limitations such as ignoring the topology of the regulatory networks 
and the relative rank of the strength of the association. These limitations can be addressed using 
the systems biology framework incorporating qualitative and quantitative models, since these 
models consider the topology of the network and the quantitative measure of molecular 
activities (such as protein activity, mRNA† expression and metabolite concentration). Thus in 
silico systems biology is regarded as a promising avenue to discover a combination of targets 
and modulators to produce synergistic effects or avoid antagonist effects.53,54 
method.52g  
 
Figure 3: A schematic flow chart summarizing the process of drug discovery, including major 
in silico contributions (italicized) to chemistry, biology† and ADMET. 
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2 BASIC PRINCIPLES AND UNDERLYING PREMISES OF SYSTEMS BIOLOGY 
APPROACHES TO DRUG DESIGN 
Since systems biology based approaches attempt to integrate (a) metabolic/chemical 
concentrations, (b) protein activity, (c) protein expression, (d) gene expression and (e) 
phenotypic endpoints and use one as a surrogate for the other, it is vitally important to 
understand some of the underlying assumptions and foundational arguments for application of 
this strategy for drug discovery. BCL-ABL and epidermal growth factor receptor (EGFR) 
kinases are prototypical examples, which exemplify correlations between genes, transcripts†, 
proteins, and protein activity and led to conceptualization of systems biology approaches55 
(figure 4). 
 
Figure 4: BCL-ABL: correlations between gene fusion and protein activity levels. BCR-ABL 
kinase is a major drug target for a range of blood and solid tumors. Systems biology 
researchers aim to identify similar such drug targets using HT data and the conceptual 
workflow described in section 1.3. 
2.1 Correlations between mRNA and protein abundance levels 
The principle hypothesis of genomics is that steady state mRNA levels correlate with protein 
concentrations. The reported correlations between mRNA and protein levels by different 
groups vary from R= 0.4 to R=0.7.56 The limited correlation was attributed to the importance 
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of post-transcriptional-, translational- and protein degradation-regulation in controlling steady-
state protein abundances, and it was suggested that better correlations may be obtained by 
addressing experimental artefacts. 
2.2 Gene co-expression for estimating protein-protein interaction probability 
Proteins involved in regulatory interactions are assumed to have more similar gene expression 
profiles than random pairs. Supporting evidence comes from studies comparing gene 
expression profile with large-scale PPI data sets.57 Thus mRNA co-expression profiles may be 
used to infer cell-signaling networks. 
2.3 Existence of upward and downward causation in biological systems 
The advances in genetics and epigenetics unequivocally demonstrate the existence of 
downward causation (e.g., from protein to gene), which is seen as completing a feedback circuit 
and has formed the founding principle of systems biology58. Some of the most important 
downward causation events include triggers (hormones and neurotransmitters) of cell signaling, 
control of gene expression by TFs and epigenetic regulators, the protein machinery that reads 
and repairs making the genome reliable59 (as described in figure5). 
 
Figure 5: Systems biology view of upward and downward causation in biology as a feedback 
diagram. While the upward causation is well known (black links), some of major downward 
causation (blue links) elements include TFs, epigenetic regulators, reverse transcriptases, 
DNA_polymerases†, and recombinases.  
2.4 Multiple targets for structure-based drug design 
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Complex multifactorial diseases show perturbations at pathway levels and not necessarily at 
individual proteins/genes. Hence the systems biology based drug design paradigm focuses on 
searching for multi-target drugs to perturb disease-associated networks rather than designing 
selective ligands to target individual proteins. Furthermore, studies on drug promiscuity in 
proteome-wide binding60 estimated that an existing drug binds to, on average, 6.3 protein 
receptors, which include targets (favorable) and anti-targets (unfavorable). Thus given this 
promiscuity and the systems biology view of diseases, it is important to build actionable models 
(i.e., models that can predict the effect of perturbations on the relevant physiological process) 
to guide structure-based drug design (as illustrated in figure 2). 5 
2.5 Correlation between drug-induced protein activity levels and gene expression 
profiles 
The correlation between drug-induced protein activity levels and mRNA abundance is another 
founding principle of systems biology based drug design. This principle was examined by 
analyzing the protein activity and mRNA concentrations upon rapamycin treatment.61 A 
significant number of proteins with decreased activity caused decreases in their mRNA levels. 
This result may be explained by common network motifs.62 
In another study, Iskar et al63 showed similar trends after analyzing 1,290 drug-target and drug-
mRNA profiles, although the sample size was small. A recent study by Koussounadis et al 64 
showed that differentially expressed mRNAs correlate significantly better with their protein 
product than non-differentially expressed mRNAs. These results have increased confidence for 
the use of differential mRNA expression for biological discovery in various disease systems, 
as well as providing optimism for the usefulness of inferences from mRNA expression in 
general.56d, 65 
2.6 Qualitative and quantitative cell signaling models to simulate the effect of 
cues on cellular behavior and phenotype 
Qualitative and quantitative cell signaling models or network-based computational models are 
broadly classified as Bayesian, logic based (qualitative) and mass-action (quantitative) 
models.54 These models capture the dynamic signaling networks that drive biological decision 
processes and cellular states in response to cues. In a network based computational model, 
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cellular behavior (e.g., cell migration) or phenotypic states (e.g., metastatic) can be considered 
a steady state high dimensional vector of gene/protein activities66,67 
We can thus expect network-based computational models to be able to simulate diseases such 
as cancer, which are not just regarded as ones with a genetic basis but as those that are driven 
by perturbations at the signaling network level. For instance, network based computational 
models can simulate the events, involving perturbations to some network components, that 
change normal cells to new malignant states (e.g., EGF induction leading to metastasis), or the 
events, involving drug mediated perturbations, that might reverse or inhibit certain phenotypic 
states. 5, 66,67 
3 IMPORTANT ELEMENTS AND RELATIONSHIPS IN SYSTEMS BIOLOGY 
DATASETS 
Systems biology analyzes global profiles of chemicals, proteins and genes to understand and 
predict biological complexity by using a cross-disciplinary approach.68,69 Hence it integrates 
many multi-scale (genes to phenotypes) types of biological information. Systems biology data 
are best described as a graph, consisting of nodes (elements) and edges (relationships between 
elements), and analyzed using graph (network) based methods (tables 1 and 2). While Table 1 
summarizes some of the datasets that usually are integrated and used in the systems biology 
based drug design paradigm and hypotheses that can be derived from retrospective analysis, 
table 2 catalogs open access databases and software packages useful for systems biology 
approaches to drug discovery. 
Table 1: Summary of the datasets used in the systems biology based drug design paradigm and 
the nature of the hypothesis that can be inferred by analyzing these datasets.  
Data type Parts list Hypothesis from a 





Node Attributes:  Proteins, Domains, 
Substructures, Enriched fragments†, 
Pharmacophores, Toxicophores, 
Physicochemical properties, 
Structural descriptors, etc 
(a) Chemical similarity 







Node Attributes: Domain 
definitions,Ssequence motifs(linear 
(a) Protein similarity and 




Data type Parts list Hypothesis from a 
retrospective analysis of the 
interactions 
and non-linear), Superfamily 
definitions, Sequence descriptors, 
Cognate ligands, Pathways, other 






Nodes: Genes/ transcripts 
Node Attributes: 
Phenotypes/indications, 
Perturbagens† (small molecule or 
si/shRNA), motifs, regulators (TFs, 
Epigenetic factors, Master 
regulators), Pathways, Literature 
gene sets. 
 
(a) Finding and interpreting 
genes/ transcripts associated 




Nodes: Diseases/ Indications/ 
phenotypes 
Node Attributes: in vivo† Biochemical 
data, Hematology, Organ Weight, 
Pathology Data, Histology, Pathways, 
Genes, Proteins (drug targets), 
Chemicals, Chromatin regulators. 
(a) Studying the genotype–
phenotype map, (b) 
Identifying the genetic basis 
of complex traits. 
Chemoproteomics 
(bipartite 
networks – edges 
between chemicals 
and proteins only) 
Nodes: Chemicals, Proteins 
Edge Attributes: Activation, 
inhibition, degradation. 
(a) Analyzing the 
pharmacological map of the 
druggable proteome and 
discovering ligands for 
undruggable proteome, (b) 
drug target discovery. 
Chemogenomics 
(bipartite 
networks – edges 
between chemicals 
and genes only) 
Nodes: Chemicals, Genes 
Node Attributes: : in vivo Biochemical 
data, Hematology, Organ Weight, 
Pathology Data, Histology, Pathways, 
Genes, Proteins (drug targets), 
Chemicals, Chromatin regulators. 
Edge attributes: activation, 
repression. 
(a) Determining mode of 
action, (b) drug repurposing 






Nodes: Chemicals, Genes, Proteins, 
protein complexes, phenotypes 
Node Attributes: Activity levels 
inferred from mRNA or protein 
expression activity data. 
Edge Attributes:  
Regulatory interactions, PTMs,  
(a) Represent existing 
knowledge of biological 
systems, (b) predict the 
effect of perturbations on 
other components of the 
pathway, (c) identify 
missing components in a 
pathway, (d) determine the 
most critical components of 
the pathway,  
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Understanding complex systems often requires a bottom-up analysis which involves 
investigating a system, not only as individual components but as a whole.70 Such an 
investigation can be done by examining the elementary constituents (nodes) individually and 
then how these are connected. The myriad components of a system and their interactions are 
best characterized as networks and they are mainly represented as graphs where thousands of 
nodes are connected with thousands of vertices. 
In general, a graph based computations have been successfully applied to the study of 
biological network topology, from the global perspective of their scale-free, small world, 
hierarchical nature, to the zoomed-in view of interaction motifs, clusters and modules and the 
specific interactions between different biomolecules. 70 
In particular, network-based approaches can elucidate the cause-effect mechanisms of existing 
observations (“retrospective systems biology analysis”) by clustering entities and analyzing 
properties enriched within clusters. For example, genes can be clusters based on expression 
profiles and common regulators within a co-expressed cluster can be identified by the 
enrichment of regulator binding sites. Similarly, chemical fragments that preferentially inhibit 
a given protein family can be identified by clustering chemicals based on their protein 
interaction profiles.71.  
Weighted gene co-expression network analysis (WGCNA) is one of the best suited data mining 
methods for retrospectively analyzing the various systems biology data described above. 
Though it can be applied to most systems biology data sets, it has been most widely used for 
cause-effect interpretation in genomics. WGCNA allows one to define modules (clusters) and 
intramodular hubs, correlate the modules with attributes or perform enrichment analysis. Some 
of the typical hypotheses derived from retrospective analysis of the systems biology databases 
described in table 1 are discussed below. 
Table 2: Open access databases and free software and tools for retrospective analysis. Only 
tools used and verified by the authors are presented. 
Data type Open access 
Datasets and tools 
to import 








Data type Open access 
Datasets and tools 
to import 
Open access software 
BindingDB36, 
STITCH36 
(b) Cluster and enrichment analysis:WGCNA77, 





(a) Descriptors: Uniprot.WS, Protr82, Rcpi75, 
BioMartR.83 
(b) Cluster and enrichment analysis: WGCNA77, 
Fabia78, Bicluster, SuperBicuster. 
Genomics NCBI GEO84, 
Arrayexpress84 
(a) Differential gene expression analysis: Affy85, 
Limma.52f 
(b) High Throughput Sequencing Data analysis: 
Babraham Bioinformatics86 
(b) Gene coexpression analysis: WGCNA77, 
Fabia78, SuperBicuster. 
(c )Databases for gene set enrichment analysis: 
MSigDB 49, GeneSetDB50a, ConReg, EnrichR51, 
Hippi.87 
(d) Tools for gene set enrichment analysis in 
bioconductor: SPIA88, gCMAP52a, Piano89 





(a) Cluster and enrichment analysis: WGCNA77, 




(a) Descriptors: ChemmineR73, SNG, Rcpi, 
OpenBabel, Uniprot.WS, Protr82, Rcpi75, 
BioMartR.83 
(b) Cluster and enrichment analysis:WGCNA77, 
Fabia78, Bicluster, SuperBicuster. 









(a) Differential gene expression analysis: Affy85, 
Limma52f 
Gene coexpression analysis: WGCNA, Fabia78, 
SuperBicuster 
(b) Databases for gene set enrichment analysis: 
MSigDB 49, GeneSetDB50a, ConReg, EnrichR51, 
Hippi.87 
(c ) Tools for gene set enrichment analysis in 
bioconductor: SPIA88, gCMAP52a, Piano89 








(a) import and parse systems biology models: 
KEGGgraph97 for KEGG 
(b) Network inference: CellNoptR48, BoolNetR98 
and Copasi99. 
(c )Network simulation: CellnOptR48, 





3.1 Chemoinformatics: Chemoinformatics is the field of study of all aspects of the 
representation and use of chemical and biological information on computers. Since similar 
chemical structures generally give similar activities, the identification of the links between 
chemical structures in terms of their attributes can lead to a comprehensive understanding of 
the nature of the chemical space, inform SAR and polypharmacological profiles, and provide 
mode of action (MOA) hypotheses for orphan compounds.102 The chemical similarity network 
analysis can also complement chemoproteomic and chemogenomic analysis and provide a 
more complete hypothesis for drug discovery research. 
3.2 Proteomics: Proteomics is the large-scale study of proteins, particularly their 
structures and functions. It is broadly divided into abundance and functional proteomics. While 
abundance proteomics catalogs protein components, identifies differences between states, finds 
biomarker and examines post-translational modifications, functional proteomics identifies 
interactors (PPIs, signal transduction pathways, biochemical machinery), finds enzymatic 
substrates and studies drug selectivity profiles. The comprehensive characterization of protein 
similarity and PPI networks can provide useful hypothesis for binding site predictions, and 
inform on polypharmacology profiles to guide rational optimization of the efficacy and 
toxicity.103 The now mature field of PPI network analysis has led to considerable successes in 
identifying protein modules related to important biological processes and diseases. 
3.3 Genomics Genomics is a discipline in genetics that applies recombinant DNA, 
DNA sequencing and bioinformatics to sequence, assemble and analyze the function and 
structure of genomes. Genomics research has been used for finding and interpreting 
genes/transcripts associated with phenotypic changes or perturbations. The identification of 
events (differential expression of genes; DEG) associated with phenotypic changes is now 
routinely performed and used for developing diagnostic, prognostic and gene signature assays. 
However, methods for inferring the causative events and for understanding the cause-effect 
mechanisms are currently being developed.104 The understanding of cause-effect mechanisms 
could provide valuable new points of intervention (drug targets) for restoring the normal 
phenotypes. It could also provide important regulators for the emerging field of rational cellular 
reprogramming and phenotypic transitions.77 As the field of genomics matures the limitations 
of single gene based DEG approaches and the benefits of gene set based approaches such as 
gene set enrichment analysis (GSEA)42 and WGCNA 77 are also being recognized and driving 
the field.  
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3.4 Phenomics: Phenomics is a very broad study that deals with measuring how much 
the physical and biological traits in an organism is affected due to genetic and epigenetic 
(environmental) effects. Phenomics research contributes to an understanding genetic disorder, 
cancers and other diseases. It involves mapping genotype to phenotype either directly using 
single nucleotide polymorphism† (SNP) arrays or via the intermediate gene expression profiles 
with various phenotypic endpoints. While background normalization† of SNP arrays is major 
obstacle to SNP array based analysis, the identification of causal elements (master regulators) 
or interpreting the cause-effect relationships is an area of current phenomics research. 77, 104 
Several successful master regulators such as Oct4/Sox2/Nanog for induced pluripotent stem 
cells were identified retrospectively or prospectively using systems biology tools described in 
table 2.105 
3.5 Chemoproteomics: Chemoproteomics is a field of study linking chemicals to 
molecular targets implicated with therapeutic indications.38 Chemoproteomic analysis can be 
used for (a) analyzing known ligand-protein interactions (“druggable protein space”) and 
predicting ligands for proteins with no known small molecules (“extrapolating to the un-
druggable protein space”), (b) discovering drug targets and (c) identifying favorable sets of 
targets responsible for mediating cellular effects. For instance, Crizotinib, which was initially 
developed as a c-Met inhibitor, was also found to target ALK in NSCLCs. Since ALK 
mutations were also identified as causative events for NSCLCs, ALK was proposed as a drug 
target for this indication. 71b, 106 
3.6 Chemogenomics: Chemogenomics is the systematic screening of targeted chemical 
libraries of small molecules against the global transcriptome space or against individual drug 
target families. (such as GPCRs and kinases).  Chemogenomics analysis of datasets such as 
cMAP39 or Japanese Toxicogenomics Project datasets (TGP)93 have been used to identify well 
established gene signatures and biomarkers and several successful repurposing efforts were 
published using the tools presented in table 1.107 Further analysis of these data sets by using 
gene set analysis methods such as GSEA42, Galahad,46 Expression2Kinases47 should be able to 
provide additional hypotheses about potential pathways (and eventually drug targets) or gene 
sets perturbed by the compound of interest.  
3.7 Qualitative and quantitative network models: While all the datasets above are 
experimentally obtained global profiles, the datasets in this category are theoretical models 
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inferred using the above datasets for understanding specific diseases or pathways. We included 
this category in table 1 because these models can provide hypotheses and interpretations that 
are not available from any of the datasets above. These qualitative/quantitative models 
represent actionable cell signaling pathways and simulations can lead to the identification of 
drug targets (bottleneck proteins), master regulators (TFs and extracellular cues), missing 
components of networks, derive novel disease phenotypes (such as heterogeneous mutant 
cancer cellular states) and can be used for interpreting gene expression analysis.108 
4 REPRESENTATIONS FOR SYSTEMS BIOLOGY DATA 
The practice of systems biology (tables 2) depends upon many software tools, operating on 
many kinds of data elements from many different sources as described in table 1. These 
elements may have different attributes (properties described in table 1) and can be connected 
by different types of edges (links described in table 1), which can be directed or undirected. 
The edges/links can have physical meaning, denote functional associations or can represent 
shared characteristics between components.109 Hence the field of data integration actively 
researches appropriate frameworks that are applicable to systems biology data.  
The resource description framework (RDF) offers a simple mechanism to identify and describe 
the components and the links between systems biology data. In RDF, the elements are 
described in terms of their types, attributes and relations to other entities or elements. RDFS 
(RDF schema) is an extension of RDF and provides additional vocabulary for naming resources 
(rdfs: labels) and specifying simple type and relational hierarchies (rdfs: subclass of, rdfs: 
subproperty of). Most RDF resources (such as EBI RDF109 and bio2rdf) are now implemented 
as RDFS and can be queried using the SPARQL query language. SPARQL quires may contain 
triples patterns that can be conjunctively (AND) or disjunctively (OR) combined with 
mandatory or OPTIONAL triple query patterns.  
DrugBank110 is a prototypical systems biology database, which includes most of the datasets 
described in table 1. Hence many example protocols to query drugs (as the subject) and various 
attributes (pka, WaterSolubility, target, DrugClassificationCategory, Indication, 
Mechanismofaction) as objects are provided as a supplementary file 1. More complex quires 
can be made integrating the bio2rdf endpoint with other related databases. The readers can refer 
to EBI’s example SPARQL quires111 for additional details and bio2rdf example quires112. 
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Data warehousing is another method for integrating systems biology datasets. InterMine113 is 
an open source data warehousing framework, built specifically for the integration and analysis 
of complex systems biology data. TargetMine37 is one of the applications developed using the 
InterMine framework and was designed specifically for assisting early-stage drug discovery 
and development. It enables the creation of biological databases accessed by sophisticated web 
query tools. Parsers are provided for integrating data from many common biological data 
sources and formats along with a framework for adding your own data, as well as a powerful, 
scriptable web-service API to allow programmatic access to your data.114 
5 EXISTING RESOURCES FOR THE SYSTEMS BIOLOGY BASED DRUG 
DISCOVERY PARADIGM 
Table 1 shows multi-disciplinary systems biology datasets on different levels and in the 
previous section, we described general technologies for data integration. System biology 
discovers how function arises in dynamical systems (cells) by integrating diverse datasets and 
infers the missing links between molecules and phenotypes.  
Several projects were aimed at integrating multiple datasets and implementing a rational 
systems biology approach to drug and toxicity research115, such as Japanese TGP93, cMAP39, 
DrugMatrix95 and the LINCS33 project. In table 2, we attempt to discuss the basic structure of 
the data generated by these projects and their strengths, and highlight the missing links, which 
limit the use of these data for a systems biology approach.  
Japanese TGP93is probably one of the richest sources of in vivo and in vitro chemogneomic 
data with ~170 compounds-49K transcript profiled in different tissues, at different time points 
and at different doses (~20K GeneChip assays including histopathological data). Gene 
signatures and selected gene sensitivity markers were proposed for several toxicological end 
points but further analysis is required to translate these signatures into anti-targets of interest 
to drug research. However, a limited number of compounds and a lack of human in vivo or in 
vitro samples are some of the limitations of the dataset. Since no chemoinformatic or 
chemoproteomic profiles were considered this protocol has to be further appended by 
integrating it with chemoinformatic and chemoproteomic datasets to incorporate target 
identification and structure based drug design aspects. 
21 
 
DrugMatrix95 was designed along the same lines as the Japanese TGP with 600 compounds, 
including ~4,000 dose time–tissue combinations, ~2 million dosed tissue samples, ~18,000 
microarrays†, ~127,000 histopathology measurements and ~100,000 haematology and 
chemistry measurements. Furthermore, more than 800 compounds were profiled across 130 in 
vitro pharmacology assays. Like the Japanese TGP, several gene signatures and selected gene 
sensitivity markers were proposed for the several toxicological end points but further analysis 
is required to translate these signatures into anti-targets of interest to drug research. Since 
DrugMatrix is designed along the same lines as Japanese TGP, it has the same limitations and 
needs to be integrated with chemoinformatic and chemoproteomic datasets to be useful for 
drug discovery projects. 
The connectivity map39 is the most cited of the chemogenomics datasets and includes 453 
Affymetrix profiles for 164 drugs across multiple cell lines, doses and time points. Several 
repositioning hypothesis were validated and proposed using positive correlation of 
transcriptional profiles with other drugs. It has limitations similar to those with the Japanese 
TGP. In addition, no phenotypic endpoints were measured/reported but can be inferred by 
linking to ATC or ICD or sider codes. 
The Library of Integrated Cellular Signatures (LINCS)33 is an NIH funded program for the 
generation of perturbational profiles across multiple cell and perturbation types, as well as read-
outs, at a massive scale. To date, LINCS has generated over 1 billion data points of 
perturbational profiles spanning small-molecules and genetic gain- and loss-of-function across 
multiple cell types. It currently includes (~5K small molecules+ ~22K CRISPR or cDNA 
constructs) -induced molecular (1,000 landmark genes+500 kinome) and cellular signatures 
(876 cell lines). This massive project aims to create a network-based understanding of biology 
by cataloging changes in gene expression and other cellular phenotypes. The LINCS project 
addressed most of the limitations of its predecessor the cMAP build 1 and 2 and integrated the 
chemogenomics dataset with chemoproteomic and chemoinformatic datasets together with 
several other relevant datasets (e.g., compound-cell perturbations, shRNA-gene perturbations, 
and kinome scans). However, since only expression profiles of 1000 landmark genes are 
currently available, LINCS cannot readily be analyzed with conventional approaches such as 
GSEA. In addition, LINCS does not include cell signaling networks and hence cannot be used 




6 MACHINE-LEARNING METHODS FOR PROSPECTIVE SYSTEMS BIOLOGY 
DATA ANALYSIS 
While the software and tools described in table 2 are mostly used for retrospective analysis (see 
section 3), network-based approaches can be used for prospective predictions as well, for 
example, proposing novel biomarkers and validating them by new experiements.116 In 
particular, recent advances in machine-learning methods have brought about the possibility of 
applying these methods to prospective systems biology data analysis. Systems biology data 
described above have many-to-many relationships (many drugs associate with many targets) 
and are best analyzed using advanced machine-learning methods. 
Drug repurposing is the most sought after predictive hypothesis generation application and the 
numerous approaches which can be classified as similarity based, 3D structure based, network 
inference, machine learning are summarized in table 3. As seen from the cited examples in 
table 3, many methods with unique applicability ranges have already been used for drug 
repositioning studies. As suggested by Meslamani et al.117 there is no rationale for considering 
a single profiling method for drug repositioning. On the basis of a comparative evaluation of 
several ligand-based and target-based methods in profiling 157 diverse ligands on 2556 
different targets, Meslamani et al 118previously shown that (i) ligand-centric methods should 
be used whenever possible (which means when enough ligands are known for a particular 
target), (ii) 2D ligand descriptors are usually preferred to 3D descriptors, with the exception of 
low molecular-weight apolar ligands, (iii) protein−ligand docking should be reserved to polar 
and buried active sites of known structure for which few ligands are available, and (iv) 
receptor−ligand pharmacophore search may then be applied to all other protein structures. 118 
Traditional methods in machine learning and statistics provided data-driven models for 
predicting a single target or label (Y) either as binary values in classification and real-values in 
regression. However in recent years, novel application domains such as systems biology 
datasets have triggered fundamental research on more complicated problems, where multi-
target predictions are required.119 In the realm of systems biology, the targets (Ys) often have 
diverse relational structures; for instance, biological attributes or entities such as international 
classification of diseases (ICD) 10/9 annotations, protein domain annotations, Gene Ontology 
terms, all of which have parent child relationships, while gene co-expression, protein- and 
chemical- similarity networks are known to be scale-free or follow power law relationships and 
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can be presumed to have a tree shaped hierarchy. Thus a range of machine learning methods 
have to be considered depending on the data types such as support vector machines (SVMs), 
neural networks (NN), k-nearest neighbors (kNN), boosting methods for unrelated multi-label 
datasets and similarity based approaches such as DT-hybrid, kernel regression methods such 
as lasso or elastic nets or pairwise kernel method (PKM) for related multi-label datasets. 105a-d 
Table 3: Systems biology based prospective methods for drug repositioning can be classified 
as similarity-, 3D structure-, network inference- and machine learning-based methods. Some 
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In this article, we present a case for a systems biology approach to drug discovery research 
given the issues with either ligand-based or structure-based approaches for mitigating 
efficacy and toxicity. Some of the foundational principles and presumptions of systems or 
network approaches were discussed together with representative multi-scale databases used in 
systems biology research and different tools used to retrospectively or prospectively analyze 
the data together with the data models used to best capture and retrieve systems biology data. 
Given the enormous advances in computing technologies, miniaturization and HT 
experimental technologies, systems biology approaches have enormous potential to change 
the landscape of healthcare and contribute to drug discovery research. 
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